Sugi Predict

Sugi Predict / Compounds / SCHEMBL2554330

SCHEMBL2554330

SCHEMBL2554330

COC(CN)Cc1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 4/20 0.48
▸ SLC6A2 P23975 2/20 0.48
▸ SIGMAR1 Q99720 2/20 0.48
▸ MAOA P21397 1/20 0.48
▸ SLC6A4 P31645 1/20 0.48
▸ SLC6A3 Q01959 1/20 0.48
▸ CYP2A6 P11509 1/20 0.48
▸ ADORA2A P29274 1/20 0.48
▸ ADORA1 P30542 1/20 0.48
▸ EPHX1 P07099 1/20 0.46
▸ CYP2D6 P10635 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.44
▸ LAP3 P28838 1/20 0.43
▸ LOXL2 Q9Y4K0 1/20 0.41
▸ SLC18A2 Q05940 1/20 0.41
▸ ANPEP P15144 1/20 0.41
▸ GRIN2D O15399 1/20 0.40
▸ GRIN3B O60391 1/20 0.40
▸ ADRA1D P25100 1/20 0.40
▸ ADRA1A P35348 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9546973 1.00 TAAR1 (0.48) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL791591 0.87 TAAR1 (0.50) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL11511087 0.86 TAAR1 (0.46) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL25153003 0.85 MAOB (0.57) SLC6A2SIGMAR1MAOASLC6A3LAP3
SCHEMBL12569402 0.84 ALDH1A1 (0.53) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL11565795 0.81 ALDH1A1 (0.46) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL8441498 0.81 TRPA1 (0.47) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL12847348 0.80 TAAR1 (0.45) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL2554011 0.80 TAAR1 (0.50) TAAR1SLC6A2SIGMAR1MAOASLC6A4
SCHEMBL4405219 0.80 SLC6A4 (0.58) TAAR1SLC6A4CYP2D6ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260007672-A1 INHIBITORS OF MPTP NRG THERAPEUTICS LTD (GB) 2026-01-08 — — US disclosed
US-12491185-B2 Inhibitors of mPTP NRG THERAPEUTICS LTD (GB) 2025-12-09 — — US disclosed
EP-4652162-A1 INHIBITORS OF MPTP NRG Therapeutics LTD (GB) 2025-11-26 — — EP disclosed
US-20250177397-A1 INHIBITORS OF MPTP NRG THERAPEUTICS LTD (GB) 2025-06-05 — — US disclosed
WO-2024153946-A1 INHIBITORS OF MPTP NRG THERAPEUTICS LTD (GB) 2024-07-25 — — WO disclosed
CN-117623935-A Method for preparing amine compound by reductive amination of molecular sieve-based metal catalyst 浙江大学 2024-03-01 — — CN disclosed
US-11173144-B2 Adrenergic receptor modulating compounds and methods of using the same THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2021-11-16 — — US disclosed
US-20200237724-A1 ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY 2020-07-30 — — US disclosed
EP-3454845-A1 ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME The Board of Trustees of the Leland Stanford Junior University (US) 2019-03-20 — — EP disclosed
WO-2017197324-A1 ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2017-11-16 — — WO disclosed
CN-102295642-B 2-Aryimidazole is [1,2-a] pyridine-3-acetamide, Preparation Method And The Use also Institute of Toxicology and Drugs, Chinese Academy of Military Medical Sciences (CN) 2016-04-06 — — CN disclosed
CN-104812387-A Substituted 1, 6-naphthyridines HOFFMANN LA ROCHE 2015-07-29 — — CN disclosed
EP-2555623-A1 FLAVIN DERIVATIVES BioRelix, Inc. (US) 2013-02-13 — — EP disclosed
US-20130029980-A1 FLAVIN DERIVATIVES COISH PHILIP D G (US) 2013-01-31 — — US disclosed
US-20130029980-A1 FLAVIN DERIVATIVES COISH PHILIP D G (US) 2013-01-31 — — US disclosed
US-20130029980-A1 FLAVIN DERIVATIVES COISH PHILIP D G (US) 2013-01-31 — — US disclosed
CN-102295642-A 2-aryl imidazo [1,2-a] pyridine-3-acetamide derivative and preparation method as well as application thereof — 2011-12-28 — — CN disclosed
WO-2011126567-A1 FLAVIN DERIVATIVES BIORELIX, INC. (US) 2011-10-13 — — WO disclosed
WO-2011126567-A1 FLAVIN DERIVATIVES BIORELIX, INC. (US) 2011-10-13 — — WO disclosed
EP-0543861-A1 IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION BRITISH BIO-TECHNOLOGY LIMITED (GB) 1993-06-02 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130029980-A1 FLAVIN DERIVATIVES BLVRB, FLAD1, FDPS TAAR1 3574/4885SLC6A2 3041/4885SIGMAR1 2273/4885
US-20200237724-A1 ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME ADRB1, ADRB2, ADRA1B TAAR1 116/4885SLC6A2 469/4885SIGMAR1 171/4885
US-12491185-B2 Inhibitors of mPTP PARK7, PINK1, SNCA TAAR1 728/4885SLC6A2 45/4885SIGMAR1 680/4885
US-11173144-B2 Adrenergic receptor modulating compounds and methods of using the same ADRB1, ADRB2, ADRA1B TAAR1 116/4885SLC6A2 469/4885SIGMAR1 171/4885
US-20250177397-A1 INHIBITORS OF MPTP PARK7, PINK1, SNCA TAAR1 728/4885SLC6A2 45/4885SIGMAR1 680/4885
US-20260007672-A1 INHIBITORS OF MPTP PARK7, SNCA, CYC1 TAAR1 195/4885SLC6A2 85/4885SIGMAR1 60/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.